Hangzhou Beiputai Biopharmaceutical Co., Ltd.

Established in 2023, Hangzhou Beiputai Biopharmaceutical Co., Ltd. is a high-tech enterprise focusing on the R&D and sales of polypeptides and related derivatives. The company has established a polypeptide R&D center in the Overseas Student Entrepreneurship Park in Qiantang District, Hangzhou. It is equipped with several polypeptide R&D production lines and large-scale analytical equipment such as Agilent high-performance liquid chromatography and AB mass spectrometry. The R&D team has more than 10 years of polypeptide experience and can meet personalized customization. Products include GLP-1 polypeptides (Smeglutide, Tirpopeptide, Retalutide, etc.), small molecule mimetic peptides, radioimaging polypeptide precursors (RDC precursors, such as FAPI/PSMA/Oct), PDC polypeptides, polypeptide inhibitors (aldehyde peptides/FMK/CMK, etc.), luciferase substrates, glycopeptides, isotope-labeled peptides, macrocyclic polypeptides, maps complex antigen peptides, fluorescent labeled peptides, cell transmembrane peptides, etc. More than 100 mature polypeptides have been produced, with an annual output of more than 100 kg of polypeptides.

Hangzhou Beiputai Biopharmaceutical Co., Ltd. is located at Building 2, Room 369, No. 21, Baiyang Street Dao Avenue Hao, Qiantang District, Hangzhou, China.

Main peptides produced: Tirzepatide, Retatrutide, Semaglutide, BPC-157.

Website: https://www.beiputaibio.com